Selective Cancer Treatment Technology


The technology represents optimization and monitoring by MRI of nano sized cancer drug release in deep tumor regions. Aiming for cure for those 20 % who die from local complications. Lead time to market 1 - 2.5 y. Approved patents. USD 0.45 mill.

Listing Information

Posted by Gunnar Myhr Ph. D. under

  • check icon Product Idea/Concept
  • check icon Patent for Sale
  • check icon Original Creative Works
  • check icon Trademark
  • check icon IP Portfolio
  • check icon IP Wanted
  • check icon Other
Selective Cancer Treatment Technology
Contact This Person

Full Description

CancerCure Technology - www.cctech.no

CancerCure Technology Ltd. (CCT) is a company working on Magnetic Resonance (MR) guided cancer treatment systems and selectively induced drug release for significantly improved therapeutic index (survival). The technology represents real time monitoring, novel combinations and optimization of current treatment regimes. Lead time to market – 2.5 years. The technology is patented (approved). Total market size USD 45 bill. (2004).

Oncological objectives

  • Aiming for cure for those 20 % who die from local complications.
  • Significant increase in therapeutic index (5-year survival) for those 80 % who die from metastases.

Cooperating bodies

CCT has a development agreement with Rikshospitalet (The National Hospital of Norway), close ties to The Radium Hospital and The Norwegian University of Science and Technology. The Company has received a grant (NOK 3.5 mill.) from "Innovation Norway" and is approved for "Skattefunn" (20 % refund of R&D expenditures) by the Research Council of Norway.


Myhr G. Multimodal cancer treatment: Real time monitoring, optimization, and synergistic effects. Technol Cancer Res Treat 2008;5; 409-414.

 Myhr G. MR guided cancer treatment system for an elevated therapeutic index – a macroscopic approach. Med Hypotheses 2008;70; 665-670.

 Myhr G. Multimodal ultrasound mediated drug release model in local cancer therapy. Med Hypotheses 2007;69; 1325-1333.

Myhr G, Moan J. Synergistic effects of chemotherapy and ultrasound treatment. Cancer Letters 2006;232; 206-213.


MR guided cancer treatment system. Patent No.: GB 07116662.7
Priority date: June 15, 2007.
UK/USA. Approved by UK patent authorities.

Therapeutic Ultrasound System. Patent No.: WO 2006/129099
Priority date: June 2, 2005 (UK). Approved IPER by the PCT.

Therapeutic probe, method and system. US Patent No.: 7,220,258
Granted: USA, February 2007.

Apparatus for selective cell destruction within a living organism. Patent No.: PCT/NO2001/000349. Granted: Norway, April 2002, EPO (DE, ES, FR, UK, IT), July 2005. Pending USA.